GlycoMira Therapeutics is developing therapeutics for Mucosal Diseases. Current R&D focus on mitigating radiation-induced injuries (Oral Mucositis & Acute Radiation Syndrome) and chronic rhinosinusitis.
View Top Employees from GlycoMira Therapeutics, Inc.Website | http://www.glycomira.com |
Revenue | $1 million |
Employees | 8 (5 on RocketReach) |
Founded | 2008 |
Address | 675 Arapeen Drive Ste 302, Salt Lake City, Utah 84108, US |
Phone | (801) 649-3999 |
Technologies |
JavaScript,
HTML,
PHP
+4 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Business Services General, Anti-Inflammatory, Business Services, Mucositis, Periodontitis, Glycobiology, Radiation Biology, Inflammation, Cancer Supportive Care, Palliative Care |
Web Rank | 19 Million |
Keywords | Glycot Therapeutics |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular GlycoMira Therapeutics, Inc. employee's phone or email?
The GlycoMira Therapeutics, Inc. annual revenue was $1 million in 2024.
Justin Savage is the Vice President of Operations of GlycoMira Therapeutics, Inc..
5 people are employed at GlycoMira Therapeutics, Inc..
GlycoMira Therapeutics, Inc. is based in Salt Lake City, Utah.
The NAICS codes for GlycoMira Therapeutics, Inc. are [54171, 5417, 541714, 54, 541].
The SIC codes for GlycoMira Therapeutics, Inc. are [873, 87].